18:41 , Sep 1, 2017 |  BioCentury  |  Finance

Armo's China network

Chinese investors in Armo BioSciences Inc. 's $67 million series C-1 round could help the Redwood City, Calif., company establish local partnerships and bring its lead cancer therapy to the China market. Qiming Venture Partners...
18:04 , Sep 1, 2017 |  BC Week In Review  |  Financial News

Armo raises $67M series C-1 round

On Aug. 29, Armo BioSciences Inc. (Redwood City, Calif.) raised $67 million in an untranched series C-1 round led by Qiming Venture Partners. Fellow new investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments...
22:14 , Aug 29, 2017 |  BC Extra  |  Financial News

Armo raises $67M series C-1 round

Armo BioSciences Inc. (Redwood City, Calif.) raised $67 million in an untranched series C-1 round led by Qiming Venture Partners. Fellow new investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments also participated, along...
08:00 , Feb 15, 2016 |  BioCentury  |  Finance

Combo collector

Armed with a $50 million series C round, Armo BioSciences Inc. plans to move into pivotal cancer studies of immunotherapy combinations that include its AM0010 . The initial plan is to combine the recombinant pegylated...